Impacct: infrastructure for musculoskeletal pediatric acute care clinical trials
Active Cooperative Agreement Awarded Last action
- Award ID
- U01AR079113
- Recipient
-
ANN & Robert H Lurie Childrens Hospital Of Chicago UEI XJ7MMPHBMGM7
- Awarding agency
-
National Insititue of Arthritis and Musculoskeletal and Skin Diseases
National Institutes of Health, Department of Health and Human Services
- Obligated
- $6,455,620
Award facts
- Assistance listing
- 93.846 Arthritis, Musculoskeletal and Skin Diseases Research
- Completion date 94% complete
- Originally
- Funding
-
- $6,305,620.00 Federal
- $150,000.00 Non-federal
- Funding agency
- National Institute of Child Health and Human Development National Institutes of Health, Department of Health and Human Services
- Place of performance
- Chicago, IL 60611, USA
Award details come from USAspending.gov.
Description
- Abstract
- The management of two common upper extremity injuries, pediatric medial epicondyle fractures (MEF) and displaced distal radius fractures (DRF), is controversial with high practice variation. The debate largely focusses on whether to reduce these injuries to restore their usual position or to allow the fractures to heal in their injured position with simple immobilization. Observational studies support both reduction and simple immobilization for MEF and DRF. In both injuries, there have been few prospective and no randomized studies evaluating their treatment. Given the widespread variation in practice, children are either undergoing unnecessary procedures and anesthetic events when surgeons OPT for reduction under anesthesia/ conscious sedation or are being undertreated by simple immobilization. Both scenarios are unacceptable in that children face either anesthetic risks and extra costs or poor alignment with potential long term functional disability to address such clinical dilemmas, the infrastructure for musculoskeletal pediatric acute care clinical trials (impacct) consortium was organized to develop the infrastructure and experience necessary for multicenter randomized clinical trials. Impacct's leadership has expertise in leading multicenter clinical trials and its members represent 32 diverse centers from the pediatric orthopaedic society of north america (posna). During the impacct consensus conference, participants agreed that that MEF and DRF have the equipoise necessary and are the most pressing clinical controversies. A similar priority-setting study from the united kingdom identified these questions as important controversies in children's orthopaedic surgery. Posna-wide surveys confirmed MEF and DRF treatment variation and surgeons' willingness to randomize. A multicenter randomized superiority trial of children with MEF and DRF is required to evaluate the clinical effectiveness of reduction under anesthesia/sedation VS. Simple immobilization. The central hypothesis of this proposal is that children treated with reduction under general anesthesia (MEF) or conscious sedation (DRF) will have higher patient reported outcome scores compared to those treated with simple immobilization alone. Trials on both fractures will be conducted simultaneously to take advantage of the economy of scale and are similar in terms of anatomic location, outcome measures, and whether an intervention is necessary. Thirty- one sites have agreed to recruit, randomize and treat a total of 688 patients according to the pragmatic protocols. Investigators have partnered with the trial innovation network to increase the efficiency of trial development and execution. Niams has awarded this initiative an R34 clinical trials planning grant. This proposal will support the active study phase when patients are recruited, treated, and followed and when results are analyzed and disseminated. The completion of these trials will provide a framework, infrastructure and experience for future prospective multicenter clinical trials in pediatric orthopaedics as its results guide clinical decision-making.
Transactions
| Action | Federal | Non-federal | Date |
|---|---|---|---|
| Amendment | $967,917 | $0 | |
| Amendment | $135,000 | $0 | |
| Amendment | $0 | $0 | |
| Amendment | $0 | $0 | |
| Amendment | $0 | $0 | |
| Amendment | $0 | $0 | |
| Amendment | $0 | $0 | |
| Amendment | $0 | $0 | |
| Amendment | $0 | $0 | |
| Amendment | $0 | $0 | |
| Amendment | $0 | $0 | |
| Amendment | $150,000 | $0 | |
| Amendment | $150,000 | $0 | |
| Amendment | $0 | $0 | |
| Amendment | $0 | $0 | |
| Amendment | $1,291,462 | $0 | |
| Amendment | $148,500 | $0 | |
| Amendment | $1,291,462 | $0 | |
| Amendment | $148,500 | $0 | |
| Amendment | $1,572,779 | $0 | |
| Amendment | $150,000 | $0 | |
| Amendment | $150,000 | $0 | |
| Original award | $150,000 | $150,000 |
Show all 23
Subawards
Show all 29
Quick answers
Who received award U01AR079113?
U01AR079113 was awarded to ANN & Robert H Lurie Childrens Hospital Of Chicago by National Insititue of Arthritis and Musculoskeletal and Skin Diseases (National Institutes of Health) on September 1, 2021.
How much is award U01AR079113 worth?
$6,455,620 has been obligated on U01AR079113: $6,305,620 in federal funding and $150,000 in non-federal funding.
Which agency awarded U01AR079113?
National Insititue of Arthritis and Musculoskeletal and Skin Diseases (National Institutes of Health) awarded U01AR079113, with funding from National Institute of Child Health and Human Development (National Institutes of Health).
On GovTribe
See this award's full record
- Every transaction and subaward
- The recipient's other awards and teaming partners
- Similar grant awards
- Ask GovTribe AI about this award